Lixte Biotechnology Holdings, Inc.
NASDAQ Capital MarketTotal Valuation
Lixte Biotechnology Holdings, Inc. carries a market capitalization of 100,551.00, placing it among publicly traded companies globally.
| Market Cap | 100,551.00 |
| Enterprise Value | N/A |
Share Statistics
Lixte Biotechnology Holdings, Inc. currently has 11.63M shares outstanding.
| Shares Outstanding | 11.63M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Lixte Biotechnology Holdings, Inc. maintains a current ratio of 2.78, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.78 |
| Quick Ratio | 2.65 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -700.53 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -116.70 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Lixte Biotechnology Holdings, Inc.'s stock has declined approximately -26.33333% over the past 52 weeks. The 50-day moving average sits at 0.13, while the 200-day moving average is 0.11.
| Beta (5Y) | N/A |
| 52-Week Price Change | -26.33333% |
| 50-Day Moving Average | 0.13 |
| 200-Day Moving Average | 0.11 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -6.39M, while operating income came in at -6.39M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -6.39M |
| Pretax Income | -7.29M |
| Net Income | -7.22M |
| EBITDA | -6.39M |
| EBIT | -6.39M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at -60.00M, with working capital of 2.18M providing operational flexibility.
| Cash & Cash Equivalents | 3.25M |
| Total Debt | N/A |
| Net Debt | -3.25M |
| Equity (Book Value) | -60.00M |
| Book Value Per Share | N/A |
| Working Capital | 2.18M |
Cash Flow
Lixte Biotechnology Holdings, Inc. produced -4.33M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.33M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.33M |
| FCF Per Share | N/A |
Dividends & Yields
The company's payout ratio of 1.17 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 1.17 |
| Shareholder Yield | N/A |
| FCF Yield | N/A |
Scores
Lixte Biotechnology Holdings, Inc. posts an Altman Z-Score of -9.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -9.43 |